Michael Gillen

863 total citations
55 papers, 693 citations indexed

About

Michael Gillen is a scholar working on Pulmonary and Respiratory Medicine, Nephrology and Physiology. According to data from OpenAlex, Michael Gillen has authored 55 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 22 papers in Nephrology and 21 papers in Physiology. Recurrent topics in Michael Gillen's work include Asthma and respiratory diseases (21 papers), Gout, Hyperuricemia, Uric Acid (21 papers) and Inhalation and Respiratory Drug Delivery (16 papers). Michael Gillen is often cited by papers focused on Asthma and respiratory diseases (21 papers), Gout, Hyperuricemia, Uric Acid (21 papers) and Inhalation and Respiratory Drug Delivery (16 papers). Michael Gillen collaborates with scholars based in United States, United Kingdom and Sweden. Michael Gillen's co-authors include Zancong Shen, Jesse Hall, Philip Chaikin, Jeffrey N. Miner, Sha Liu, David M. Wilson, Bradley M. Kerr, Joel Morganroth, David J. Roberts and Shashank Rohatagi and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of Pharmaceutical Sciences and Lara D. Veeken.

In The Last Decade

Michael Gillen

55 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Gillen United States	17	239	179	170	155	110	55	693
Krzysztof Mucha Poland	15	137 0.6×	39 0.2×	69 0.4×	141 0.9×	27 0.2×	78	784
Kuo-Hsiung Shu Taiwan	12	110 0.5×	57 0.3×	47 0.3×	122 0.8×	54 0.5×	16	553
Yoichi Takeuchi Japan	11	183 0.8×	126 0.7×	105 0.6×	55 0.4×	14 0.1×	27	628
Masaya Yamanouchi Japan	10	468 2.0×	76 0.4×	38 0.2×	105 0.7×	33 0.3×	16	1.1k
Manuela Berger United States	16	51 0.2×	57 0.3×	62 0.4×	244 1.6×	46 0.4×	24	857
Jeremy Puthumana United States	14	239 1.0×	74 0.4×	132 0.8×	131 0.8×	35 0.3×	17	893
Joan López-Hellín Spain	15	115 0.5×	227 1.3×	90 0.5×	193 1.2×	29 0.3×	31	770
Sameh R. Abul‐Ezz United States	14	122 0.5×	19 0.1×	111 0.7×	105 0.7×	147 1.3×	26	800
Moo Nahm Yum United States	13	134 0.6×	27 0.2×	94 0.6×	92 0.6×	71 0.6×	19	732
M Ruddel United States	17	163 0.7×	83 0.5×	61 0.4×	155 1.0×	20 0.2×	38	846

Countries citing papers authored by Michael Gillen

Since Specialization

Citations

This map shows the geographic impact of Michael Gillen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Gillen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Gillen more than expected).

Fields of papers citing papers by Michael Gillen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Gillen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Gillen. The network helps show where Michael Gillen may publish in the future.

Co-authorship network of co-authors of Michael Gillen

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Gillen. A scholar is included among the top collaborators of Michael Gillen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Gillen. Michael Gillen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aurivillius, Magnus, et al.. (2023). Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential. Pulmonary Pharmacology & Therapeutics. 83. 102245–102245. 4 indexed citations

Maes, Andrea, et al.. (2021). Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials. Clinical Drug Investigation. 41(6). 579–590. 4 indexed citations

Huang, Ying, Pryseley Nkouibert Assam, Cong Feng, et al.. (2020). Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. Pulmonary Pharmacology & Therapeutics. 64. 101976–101976. 2 indexed citations

Ishikawa, Kensuke, et al.. (2020). Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients With Renal Impairment. Journal of Pharmaceutical Sciences. 110(1). 438–445. 4 indexed citations

Chen, Qian, Chaoying Hu, Hui Yu, et al.. (2019). Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. Clinical Therapeutics. 41(5). 897–909.e1. 11 indexed citations

Fakih, Faisal, Selwyn Spangenthal, Barry Sigal, et al.. (2018). Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease. Respiratory Medicine. 138. 74–80. 10 indexed citations

Hall, Jesse, Michael Gillen, Sha Liu, et al.. (2018). Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects. Drug Design Development and Therapy. Volume 12. 1799–1807. 10 indexed citations

Fleischmann, R., Peter Winkle, Jeffrey N. Miner, et al.. (2018). Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open. 4(1). e000584–e000584. 37 indexed citations

Fleischmann, Roy, Peter Winkle, Jesse Hall, et al.. (2018). Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD Open. 4(1). e000647–e000647. 11 indexed citations

10.

Gillen, Michael, et al.. (2018). Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort® (budesonide/formoterol) pressurized metered dose inhaler. Pulmonary Pharmacology & Therapeutics. 52. 7–17. 11 indexed citations

11.

Shen, Zancong, et al.. (2017). Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects. Drug Design Development and Therapy. Volume 11. 2077–2086. 35 indexed citations

12.

Martin, Paul, Michael Gillen, James M. Ritter, et al.. (2016). Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies. Drugs in R&D. 16(1). 93–107. 34 indexed citations

13.

Martin, Paul, Michael Gillen, David Millson, et al.. (2016). Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies. Drugs in R&D. 16(1). 81–92. 15 indexed citations

14.

Flanagan, Talia, et al.. (2016). Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies. European Journal of Clinical Pharmacology. 73(2). 185–195. 9 indexed citations

15.

Martín, Paul, Stuart Oliver, Michael Gillen, Thomas Marbury, & David Millson. (2015). Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies. Clinical Therapeutics. 37(12). 2823–2836. 11 indexed citations

16.

Gummesson, Anders, Haiyan Li, Michael Gillen, et al.. (2014). Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects. Clinical Drug Investigation. 34(11). 763–772. 4 indexed citations

17.

Elsby, Robert, et al.. (2010). The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672. Drug Metabolism and Disposition. 39(2). 275–282. 19 indexed citations

18.

Tronde, Ann, Michael Gillen, Lars Borgström, Jan Lötvall, & Jaro Ankerst. (2008). Pharmacokinetics of Budesonide and Formoterol Administered Via 1 Pressurized Metered‐Dose Inhaler in Patients With Asthma and COPD. The Journal of Clinical Pharmacology. 48(11). 1300–1308. 20 indexed citations

19.

Tronde, Ann, et al.. (2008). Pharmacokinetics of budesonide and formoterol administered via a series of single‐drug and combination inhalers: four open‐label, randomized, crossover studies in healthy adults. Biopharmaceutics & Drug Disposition. 29(7). 382–395. 18 indexed citations

20.

Rohatagi, Shashank, et al.. (2001). Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 39(3). 126–134. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact